09/11/2021 (Agence Europe) – The European Medicines Agency (EMA) announced on Monday 8 November that it would provide additional guidance to Member States' health authorities on the oral antiviral drug molnupiravir (see EUROPE 12819/21), with a view to authorising the use of this possible Covid-19 treatment for emergency situations. Molnupiravir, developed by Merck, was approved last week in the UK, but is still awaiting market authorisation in Europe. The EMA is continuing to work on this. However, in view of the increasing rates of infection and death due to Covid-19 in the EU (see EUROPE 12826/11), the organisation deems it necessary to provide recommendations “in the shortest possible timeframe” to the EU27 “to help national authorities decide on possible early use of the medicine”. The EMA is not authorised to make such a decision at European level. (AC)